financetom
Business
financetom
/
Business
/
Why Advent Technologies (ADN) Stock Is Skyrocketing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Advent Technologies (ADN) Stock Is Skyrocketing
Nov 4, 2024 12:02 PM

Advent Technologies Holdings Inc ( ADN ) shares are trading higher by 100% to $3.81 during Monday’s session after the company announced that its Greek subsidiary's RHyno Project has received a €34.5 million grant from the EU Innovation Fund. The company says this grant supports Advent’s advancements in clean energy technology.

Advent says the company is now set to finalize the grant agreement with the European Climate, Infrastructure and Environment Executive Agency. The company’s leadership expressed gratitude for the recognition and support from the EU Innovation Fund.

Why This Matters: Advent Technologies’ €34.5 million EU grant boosts financial stability and validates its hydrogen innovation, likely increasing investor confidence. This endorsement could position Advent for growth in the clean energy sector.

Read Also: US Stocks Likely To Open In Green Amid Hints Of Tentativeness On Election Eve: Expert Says Brace For Volatility Ahead Of Fed’s Rate Decision

According to data from Benzinga Pro, ADN has a 52-week high of $18.90 and a 52-week low of $1.71.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Baker Hughes names Ahmed Moghal as CFO
Baker Hughes names Ahmed Moghal as CFO
Feb 24, 2025
Feb 24 (Reuters) - Baker Hughes ( BKR ) said on Monday it has appointed Ahmed Moghal as its chief financial officer, effective immediately. ...
Mirum Pharmaceuticals Says US FDA Approves Cerebrotendinous Xanthomatosis' Treatment Drug
Mirum Pharmaceuticals Says US FDA Approves Cerebrotendinous Xanthomatosis' Treatment Drug
Feb 24, 2025
09:01 AM EST, 02/24/2025 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Monday that the US Food and Drug Administration has approved its Ctexli tablets, a bile acid treatment for adults with cerebrotendinous xanthomatosis, a rare genetic disorder that impairs cholesterol breakdown. The company said the approval is based on late-stage trial data showing Ctexli significantly reduced bile alcohols,...
Romania's US-backed nuclear power projects should be kept out of election row, minister says
Romania's US-backed nuclear power projects should be kept out of election row, minister says
Feb 24, 2025
BUCHAREST, Feb 24 (Reuters) - Romanian nuclear power projects backed by U.S. companies should not be affected by recent criticism from members of President Donald Trump's administration over a cancelled election, Romania's energy minister said. Romania's top court voided the country's presidential election in December based on suspicions of Russian interference in favour of the surprise far-right NATO critic frontrunner,...
High Flood Scores  Seen For Municipal Bond Offerings This Week
High Flood Scores Seen For Municipal Bond Offerings This Week
Feb 24, 2025
09:05 AM EST, 02/24/2025 (MT Newswires) -- Multiple municipal bond offerings this week have a high exposure to climate risk, specifically high Flood Scores, according to ICE Climate Data. A $15 million offering from Kingsland MUD, Texas, records a Flood Score of 4.9 out of 5.0, ICE reports. Locations with a component Physical Climate Risk Score, which includes Flood, Wildfire...
Copyright 2023-2026 - www.financetom.com All Rights Reserved